Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate


BOSTON, Massachusetts, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Radiance Biopharma, Inc., ("Radiance" or the "Company"), a biotechnology company, today announced that it has entered into an exclusive License agreement with CSPC Megalith Biopharmaceutical Co., Ltd, a subsidiary of CSPC Pharmaceutical Group Limited (CSPC; HKEX: 01093) for development and commercialization of RB-164 (SYS6005): a novel clinical stage antibody drug conjugate (ADC) targeting ROR-1. The agreement covers exclusive commercialization rights to RB-164 in the United States of America (USA), Canada, the European Union, the United Kingdom, Switzerland, Norway, Iceland, Liechtenstein, Albania, Montenegro, North Macedonia, Serbia, and Australia. CSPC will retain all rights to SYS6005 in the remaining global markets.

Read more from the original source:
Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate

Related Posts